background and objectives: hbha and mtb32c have been isolated from culture supernatants of mycobacterium tu- berculosis (m. tuberculosis) and mycobacterium bovis (m. bovis) and their immunogenicity previously studies have been confirmed. in this study, capability of constructed vector containing two mycobacterial immunodaminant antigens (mt- b32c-hbha), in producing new chimeric protein under t...

Artificial T cell receptors are under investigation as a therapy for cancer, using a technique called adoptive cell transfer. T cells are removed from a patient and modified so that they express receptors specific to the particular form of cancer. The T cells, which can then recognize and kill the cancer cells, are reintroduced into the patient. Modification of T-cells sourced from donors other...

Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural ...

T cells genetically modified to express a receptor that identifies specific antigen, known as chimeric antigen (CAR) cells, have led advancements in the treatment of hematological malignancies and tumor microenvironment. CAR-T target origin tumors on vascular side inflammatory cytokines where microenvironment forms block immunosuppressive checkpoints. The efficacy cell remains controversial bec...

background: enterotoxigenic escherichia coli (etec) strains are the major causes of diarrheal disease in humans and animals. colonization factors and enterotoxins are the major virulence factors in etec pathogenesis. for the broad-spectrum protection against etec, one could focus on colonization factors and non-toxic heat labile as a vaccine candidate. methods: a fusion protein is composed of a...

Cell therapy with T cells expressing chimeric antigen receptor (CAR-T) is a type of immunotherapy that involves the manipulation and reprogramming immune (T lymphocytes) in order to recognize kill tumor cells. For use patients, CAR-T must be manufcatured inside GMP facility according established procedure.